It's been a whirlwind of a week for EndoGastric Solutions (San Mateo, California), a company focused on the endoluminal reconstructive treatment for gastroesophageal reflux disease. On one side of the spectrum, the company reported that it has reached a $5.25 million civil settlement with the U.S. Department of Justice related to allegations that it encouraged providers to submit claims for its transoral fundoplication procedures using incorrect procedure codes, and that its co-marketing program was a potential inducement to purchase its products. On the other side of the spectrum the company reported favorable results from data from its Transoral Incisionless Fundoplication (TIF) registry.